HAEM5:T-prolymphocytic leukaemia: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
mNo edit summary |
||
| Line 120: | Line 120: | ||
|8 | |8 | ||
|Gain | |Gain | ||
|idic(8)p11 | |idic(8)(p11) | ||
t(8;8)(p11;q12) | t(8;8)(p11;q12) | ||
| Line 179: | Line 179: | ||
| | | | ||
|Minor diagnostic criteria | |Minor diagnostic criteria | ||
|- | |- | ||
|17 | |17 | ||
| Line 305: | Line 296: | ||
|None specified | |None specified | ||
|No | |No | ||
|Yes | |Yes | ||
|No | |No | ||
|''CHEK2'' mutations may indicate a defective DNA damage response and aggressive disease <ref name=":3" /><ref>{{Cite journal|last=Braun|first=Till|last2=Dechow|first2=Annika|last3=Friedrich|first3=Gregor|last4=Seifert|first4=Michael|last5=Stachelscheid|first5=Johanna|last6=Herling|first6=Marco|date=2021|title=Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact|url=https://pubmed.ncbi.nlm.nih.gov/34869023|journal=Frontiers in Oncology|volume=11|pages=775363|doi=10.3389/fonc.2021.775363|issn=2234-943X|pmc=8639578|pmid=34869023}}</ref> | |''CHEK2'' mutations may indicate a defective DNA damage response and aggressive disease <ref name=":3" /><ref>{{Cite journal|last=Braun|first=Till|last2=Dechow|first2=Annika|last3=Friedrich|first3=Gregor|last4=Seifert|first4=Michael|last5=Stachelscheid|first5=Johanna|last6=Herling|first6=Marco|date=2021|title=Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact|url=https://pubmed.ncbi.nlm.nih.gov/34869023|journal=Frontiers in Oncology|volume=11|pages=775363|doi=10.3389/fonc.2021.775363|issn=2234-943X|pmc=8639578|pmid=34869023}}</ref> | ||